Abstract 38P
Background
Patients who reach pathological complete remission (PCR) after neoadjuvant therapy for triple-negative breast cancer (TNBC) have a better overall prognosis and do not require additional adjuvant therapy postoperatively according to current guidelines; however, some patients still have a lower survival rate.
Methods
We identified TNBC patients who completed neoadjuvant therapy and achieved PCR registered in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. We analyzed the relationship between clinicopathological characteristics and overall survival, seeking to explore the high-risk factors for poor prognosis in patients who achieved PCR after neoadjuvant therapy for TNBC.
Results
A total of 1237 TNBC patients without distant metastases completed neoadjuvant therapy and achieved PCR, and their 5-year overall survival rate was 90.78%. We incorporated age, TNM stage (AJCC 7th edition), and presence of lymph node metastasis as variables to construct a multifactorial COX proportional risk model. The results found no statistically significant effect on survival time in stage II patients compared to stage I patients (HR=1.057, 95%CI 0.540-2.069, P=0.872), but statistically significant compared to stage III patients (HR=2.441, 95%CI 1.159-5.144, P=0.019). There was a statistically significant effect on survival time in patients with lymph node metastases compared to those without lymph node metastases (HR=1.913, 95%CI 1.253-2.921, P=0.003); and no statistically significant effect on survival time in patients younger than 40 years compared to those older than 40 years (HR=1.190, 95%CI 0.615-2.302, P= 0.605).
Conclusions
Younger age is not a factor influencing the prognosis of TNBC patients with PCR. For patients with stage III or lymph node metastases, even if PCR is achieved, further adjuvant therapy may be needed to improve prognosis. The type of adjuvant therapy to be used may need to be further confirmed by future prospective clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract